GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Veracyte Inc (FRA:12V) » Definitions » Institutional Ownership

Veracyte (FRA:12V) Institutional Ownership : 79.19% (As of Dec. 15, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Veracyte Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Veracyte's institutional ownership is 79.19%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Veracyte's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Veracyte's Float Percentage Of Total Shares Outstanding is 89.68%.


Veracyte Institutional Ownership Historical Data

The historical data trend for Veracyte's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Veracyte Institutional Ownership Chart

Veracyte Historical Data

The historical data trend for Veracyte can be seen below:

2024-02-29 2024-03-31 2024-04-30 2024-05-31 2024-06-30 2024-07-31 2024-08-31 2024-09-30 2024-10-31 2024-11-30
Institutional Ownership 87.73 88.93 88.05 87.35 89.52 86.93 85.33 79.66 79.03 79.19

Veracyte Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Veracyte Business Description

Traded in Other Exchanges
Address
6000 Shoreline Court, Suite 300, South San Francisco, CA, USA, 94080
Veracyte Inc is a genomic diagnostics company. It provides genomic diagnostic products and services to improve patient care against diseases such as thyroid cancer, lung cancer, and idiopathic pulmonary fibrosis. The firm's product portfolio consists of products such as Afirma analysis, Percepta, Envisia, and others.

Veracyte Headlines

No Headlines